The Voice of Canadians With Breast Cancer


Our Voices Blog

Clinical Trials in Canada: What’s currently being offered in breast cancer? - Early Stage

Title of Study: A randomised, double-blind, parallel group, placebo-controlled Phase 3 study to assess the efficacy and safety of OLAPARIB versus PLACEBO as adjuvant treatment in patients with germline BRCA 1/2 mutations and high risk HER2-negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

Patient Population: Germline BRCA 1/2 mutations and high risk HER2- primary breast cancer

Locations: Edmonton, Vancouver, Winnipeg, Hamilton, Toronto, Québec, Montreal, Greenfield Park

Click HERE for more information.

Title of Study: A Phase 3 randomized study to investigate the efficacy and safety of ATEZOLIZUMAB in combination with neoadjuvant ANTHRACYCLINE/NAB-PACLITAXEL-based chemotherapy compared with PLACEBO and chemotherapy in patients with primary invasive triple negative breast cancer

Patient Population: triple negative primary breast cancer

Locations: Oshawa, Québec, Montreal

Click HERE for more information.

Title of Study: PALbociclib CoLlaborative Adjuvant Study: A randomized Phase III trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2) – negative early breast cancer

Patient Population: Pre and postmenopausal women or men with stage II or stage III early invasive breast cancer that’s ER+ and/or PR+ and HER2-.

Locations: Abbotsford, Kelowna, Vancouver, Winnipeg, Saint John, Halifax, Kitchener, Hamilton, Toronto (PMH & Sunnybrook), Quebec, St. Catharines, Sherbrooke, Montreal (CHUM, Jewish General Hospital, MUHC Glen site), Saskatoon

Click HERE for more information

Photo by on Unsplash

Related posts